Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Where To Buy Lunesta In San Diego,.7093"

Looking for quality documents?
external link icon
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”). Approximately $309.9 million principal amount of the New Notes will be issued in exchange for approximately $217.7 million principal amount of 2024 Notes (the “Exchange Transactions”) and approximately $290.1 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $203.06 per share of Repligen’s common stock, which represents a conversion
external link icon
Repligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021
WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) (the “Company”) has commenced an offering of $100 million aggregate principal amount of Convertible Senior Notes due 2021 (the “Notes”) in an underwritten offering which includes the grant to the underwriter of a 30-day option to purchase up to an additional $15 million aggregate principal amount of Notes.  Jefferies is the sole book-running manager for the offering. 
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  The Notes will be issued and sold pursuant to an automatically effective shelf registration statement (including a base prospectus) that was previously filed with the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to this offering will be filed with the SEC. When available, copies of the
event icon
INTERPHEX
Javits Convention Center | Booth #3525
news icon
Announcing the 2014 North America Technology Fast 500™ Rankings: Annual ranking of fastest growing North America companies
corporate icon
OPUS® ValiChrom® Pre-packed Columns
LEADER OF THE PACK OPUS® ValiChrom® Columns are glass pre-packed columns that are exact scale-down models of full-scale columns, ideal for process validation, including virus clearance studies.
external link icon
Repligen Launches AAV Affinity Resins for Gene Therapy Purification
AVIPure® affinity resins address the market need for high performance and caustic stability WALTHAM, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of three advanced affinity chromatography resins for use in gene therapy manufacturing workflows. The resins – AVIPure ® - AAV9, AVIPure ® - AAV8, and AVIPure ® - AAV2 – were developed by Avitide LLC, a Repligen company, and are specific to the major adeno-associated virus (AAV) gene therapy vectors used today. AAV vectors are the leading platform for gene delivery for the treatment of a variety of human diseases 1 . Vikas Gupta, Vice President and General Manager, Downstream Bioprocessing and Gene Therapy at Repligen said, “These AVIPure resins are powerful tools in our growing arsenal of unique and differentiated solutions for gene therapy manufacturing. The outstanding performance of these resins,
video icon
Resuspension
The off bottom lift promotes a quick and efficient resuspension of settled solids. 
external link icon
Repligen Reports Second Quarter 2018 Financial Results
Record quarterly revenue of $47.7 million represents 47% year-over-year growth Revenue guidance raised to $185-$190 million for full year 2018 WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter and first half of 2018. Provided in this press release are financial highlights for the three- and six-month periods ended June 30, 2018, updates to our 2018 financial guidance and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “Our second quarter financial performance was led by record direct sales of our filtration and chromatography products, which nearly doubled year-over-year and delivered greater than 25% organic growth. Our Spectrum products continue to perform well, with 29% pro forma growth over the second quarter of 2017. In our Proteins franchise, we
external link icon
Repligen Reports Second Quarter 2017 Financial Results
Record quarterly revenue of $32.5 million First half 2017 revenue growth of 16% or 18% at constant currency Enters agreement to acquire Spectrum, Inc., which closed August 1 Prices follow-on offering which netted proceeds of $129 million Raises EPS guidance for 2017 WALTHAM, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter ended June 30, 2017. Detailed in this press release are the Company's performance highlights for the quarter, followed by updated financial guidance for the year 2017 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said “I’m extremely pleased with our accomplishments and performance during the second quarter.  We executed on our financial and strategic goals, reporting record quarterly revenue and year-to-date revenue growth of 18%. We signed
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support